Jubilant Pharma, a material wholly owned subsidiary of Jubilant Life Sciences, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg, the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.
This is the fourth approval the company has received from the USFDA during the current financial year. As on March 31, 2017, Jubilant Life Sciences had a total of 81 ANDAs for Oral Solids filed in the US, of which 51 have been approved.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
